What Health Authority Inspectors Are Looking For
FDA, EMA and MHRA inspectors share a common objective: to verify that your quality management system is functioning as designed, that your products are manufactured and controlled as described in your regulatory submissions, and that you have a culture of quality that drives continuous improvement rather than compliance management. The specific evidence they seek differs by jurisdiction — FDA is particularly focused on data integrity and CAPA effectiveness, EMA on pharmaceutical quality system maturity, MHRA on risk-based quality management — but the underlying assessment framework is consistent.
The inspectors who conduct unannounced or announced inspections at pharmaceutical and medical device manufacturing sites have typically conducted dozens or hundreds of inspections. They recognise the difference between a site that has been prepared for this specific inspection and a site whose quality systems function continuously at an inspection-ready standard. The preparation that creates the latter — not the former — is what this guide addresses.
The Twelve Weeks Before Inspection
If your inspection date is known, twelve weeks is sufficient time to close the gaps that most commonly generate observations — provided the preparation is systematic and prioritised by risk rather than by administrative convenience. If the inspection is unannounced — which is increasingly the case for FDA — your site must be at inspection readiness standard continuously, not on a twelve-week preparation cycle.
Access the complete guide
All 18 pages — practical implementation guidance, checklists and templates. Free, instant access.
No spam. No sales calls. AjaCertX will email you a copy for reference.
Guide unlocked ✓
A copy has been sent to your email for reference.
The Eight-Stage Inspection Readiness Programme
Step 01
Gap assessment against the most common inspection findings
Before beginning preparation, assess your current state against the finding categories most frequently cited by your target inspectorate. For FDA: data integrity, CAPA effectiveness, laboratory controls, and process validation. For EMA: pharmaceutical quality system, change control, qualification and validation, and product quality reviews. For MHRA: quality risk management, data governance, GMP compliance, and complaint handling. Prioritise remediation against this finding risk profile — not against the completeness of your quality system documentation.
Step 02
Documentation review and gap closure
Review your critical quality system documents: SOPs, batch manufacturing records, specifications, validation protocols and reports. Identify documents that are overdue for review, documents that describe processes that have changed without formal revision, and documents that reference obsolete equipment, processes or standards. Close these gaps systematically — document control failures are among the easiest findings for inspectors to identify and among the most damaging to your overall inspection narrative.
Step 03
CAPA system review
Review your open and recently closed CAPAs. Assess root cause quality — are root causes genuine systemic findings or superficial symptom descriptions? Assess corrective action effectiveness — have effectiveness checks been conducted and do they confirm the problem was resolved? Identify CAPAs that are overdue for effectiveness check or that have been reopened for the same or related issues. Address these specifically before the inspection.
Step 04
Data integrity assessment
Review your electronic systems — laboratory information management systems, manufacturing execution systems, QMS platforms — against your data integrity programme requirements. Verify that audit trails are enabled, that access controls are appropriate, that audit trail reviews are being conducted, and that your data integrity programme documentation reflects current system configurations. Data integrity observations have been the leading FDA 483 finding category for six consecutive years.
Step 05
Front room and back room setup
Establish your inspection management structure before the inspection. Designate: a Front Room Coordinator who manages the inspector's schedule and requests, a Back Room Coordinator who retrieves documents and coordinates subject matter specialists, and a senior management liaison who is available to address strategic questions. Conduct a dry run — simulate an inspector request and measure the time it takes to retrieve and present the response.
Step 06
SME preparation
Identify every subject matter specialist who may be interviewed during the inspection. For each: brief them on the scope of their area, the most likely questions for their function, how to answer accurately and concisely without volunteering information beyond the question asked, and what to do if they are uncertain of an answer. Practise with mock questions — not to coach scripted answers but to build the composure that comes from having thought through the likely questions in advance.
Step 07
Mock inspection
Conduct a full mock inspection using the same question structure that your target inspectorate typically applies. Use an external specialist with inspectorate experience rather than internal quality personnel — the mock must simulate an adversarial assessment, not a friendly internal audit. Document the mock findings and address them before the actual inspection.
Step 08
483 response preparation
Prepare response protocols for the most likely observation categories before the inspection. Know in advance: who has authority to accept a 483 observation, what the response drafting process is, who reviews and approves the response, and what the timeline requirements are. A 483 response submitted 30 days after inspection must be substantive — not a statement of intent. Pre-positioning the evidence for the most likely observations reduces response preparation time and improves response quality.
During the Inspection — The Five Rules
- Answer the question asked. Nothing more. The most common source of additional observations is information volunteered beyond the scope of the question. Train your SMEs to answer precisely and stop.
- Say "I don't know" when you don't know. An uncertain answer that is subsequently contradicted by documentary evidence damages credibility far more than a straightforward admission of uncertainty followed by a commitment to provide the correct information.
- Request time to retrieve documents rather than providing documents from memory. Documents retrieved and presented accurately are better evidence than documents described from memory and subsequently found to differ from the description.
- Keep the back room informed in real time. The front room should be communicating what is being discussed to the back room as it happens — not at the end of the day. Back room preparation of likely next requests creates a response capability that impresses inspectors.
- Correct errors proactively. If an incorrect statement or document is identified during the inspection, correct it proactively with the inspector. Proactive correction demonstrates quality culture. Discovery by the inspector without proactive correction suggests concealment.
Inspection Readiness Assessment Checklist
Gap assessment completed against the most common finding categories for our target inspectorate
Document control review completed — overdue reviews identified and addressed, obsolete references updated
CAPA system reviewed — root cause quality assessed, overdue effectiveness checks completed
Data integrity assessment completed and audit trail configuration verified for all electronic systems
Front room and back room structure designated with clear roles and tested response timelines
All potential SMEs briefed on inspection process and likely questions for their area
Mock inspection conducted by an external resource with inspectorate experience
483 response protocols prepared for the most likely observation categories
Preparing for a health authority inspection?
GxP inspection readiness specialists. Programme assessment within 48 hours.
About AjaCertX
AjaCertX is a specialist compliance, certification and assurance partner serving life science organisations globally. Our GxP practice delivers mock inspection services, inspection readiness programmes, and CAPA remediation for pharmaceutical, biotech and medical device organisations.